双成药业(002693) - 2017 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2017 was ¥42,587,399.38, representing a 105.36% increase compared to ¥20,738,208.12 in the same period last year[8] - The net profit attributable to shareholders of the listed company was -¥8,746,620.64, a decrease of 22.47% from -¥11,281,559.65 year-on-year[8] - The net cash flow from operating activities was -¥12,801,828.52, showing a significant increase of 738.11% compared to -¥1,527,456.54 in the previous year[8] - The basic earnings per share for the reporting period was -¥0.02, a 33.33% improvement from -¥0.03 in the same period last year[8] - The diluted earnings per share also stood at -¥0.02, reflecting the same 33.33% improvement compared to -¥0.03 year-on-year[8] - The weighted average return on net assets was -1.59%, a decrease of 0.37% from -1.22% in the previous year[8] - The company expects a net loss of between RMB 14 million and RMB 16 million for the first half of 2017, with a narrower loss compared to the same period last year[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,196,736,965.55, an increase of 2.68% from ¥1,165,528,072.32 at the end of the previous year[8] - The net assets attributable to shareholders of the listed company decreased by 1.11% to ¥547,015,239.99 from ¥553,127,627.51 at the end of the previous year[8] - Cash and cash equivalents decreased by 40.88% compared to the beginning of the period, primarily due to the use of funds for purchasing engineering and equipment[16] - Other current liabilities increased by 1028.56% compared to the beginning of the period, mainly due to a RMB 220 million interest-free loan from the controlling shareholder[17] Revenue and Costs - Operating revenue increased by 105.36% year-on-year, driven by higher product sales and improved settlement prices[18] - Operating costs rose by 44.34% year-on-year, mainly due to increased sales volume of pharmaceuticals[18] - Sales expenses surged by 829.34% year-on-year, largely due to increased market development costs following the adjustment of the marketing model[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,573[12] Government and Impairment - The company reported non-operating income of ¥531,727.42 from government subsidies during the reporting period[9] - The company confirmed an impairment loss of RMB 96.8 million on its long-term equity investment in Hangzhou Aoya Biotechnology Co., Ltd.[22] Market Developments - The company received a marketing license for Thymosin Alpha 1 injection from the Italian Medicines Agency[22] - Accounts receivable increased by 40.30% compared to the beginning of the period, attributed to adjustments in the marketing model following the implementation of the two-invoice system in the pharmaceutical industry[16]